Rebranded GeneDx Bets Future on Whole-Exome, Whole-Genome Sequencing in Pediatric Rare Disease
After dropping underdeveloped Sema4 business lines but emphasizing the Centrellis informatics platform, the new GeneDx expects to reach profitability by 2025.
CEO and Cofounder İbrahim Çağrı Kurt discussed the new test during a presentation at Slush, an annual startup conference held in Helsinki this week.
Dante Genomics, Al Farabi Medical Laboratories Partner on NGS-Based Testing in Saudi Arabia
The partners will provide whole-genome and whole-exome sequencing with interpretation as well as noninvasive prenatal testing (NIPT).
Pediatric Patients Face Barriers Receiving Exome Sequencing From Insurance, Scheduling Delays
A recent analysis found that it can take between five days and more than a year from when testing is first considered to sample collection.
Ambitions and timelines diverge, but innovators of expanded panels see broad testing as valuable to current patients and future precision oncology innovation.